Roche To Pay Nurix Up To $2.3B In Cancer Drug Deal
Swiss healthcare giant Roche said Monday that it will pay U.S. biopharmaceutical company Nurix up to $2.3 billion to codevelop and sell a therapy being developed to treat certain cancers and...To view the full article, register now.
Already a subscriber? Click here to view full article